A Novel Blood‐Based Colorectal Cancer Diagnostic Technology Using Electrical Detection of Colon Cancer Secreted Protein‐2

Abstract

Colorectal cancer (CRC) is the second‐leading cause of cancer‐related mortality worldwide, which may be effectively reduced by early screening. Colon cancer secreted protein‐2 (CCSP‐2) is a promising blood marker for CRC. An electric‐field effect colorectal sensor (E‐FECS), an ion‐sensitive field‐effect transistor under dual gate operation with nanostructure is developed, to quantify CCSP‐2 directly from patient blood samples. The sensing performance of the E‐FECS is verified in 7 controls and 7 CRC samples, and it is clinically validated on 30 controls, 30 advanced adenomas, and 81 CRC cases. The concentration of CCSP‐2 is significantly higher in plasma samples from CRC and advanced adenoma compared with controls (both P < 0.001). Sensitivity and specificity for CRC versus controls are 44.4% and 86.7%, respectively (AUC of 0.67), and 43.3% and 86.7%, respectively, for advanced adenomas (AUC of 0.67). CCSP‐2 detects a greater number of CRC cases than carcinoembryonic antigen does (45.6% vs 24.1%), and the combination of the two markers detects an even greater number of cases (53.2%). The E‐FECS system successfully detects CCSP‐2 in a wide range of samples including early stage cancers and advanced adenoma. CCSP‐2 has potential for use as a blood‐based biomarker for CRC.

Prognostic implications of metabolism-associated gene signatures in colorectal cancer

“…Whether the expression level of metabolism-related genes can be used as a prognostic maker is a vital topic of research. Our colorectal cancer prognostic model based on six metabolism-related genes was found to be of value and the 1-, 3-, and 5-year risk scores and the AUC values of ROC were consistent with previous reports ( Jeun et al, 2019 ; Park et al, 2009 ; Peng et al, 2019 ; Sun et al, 2019 ). Prognoses were classified as high- and low-risk and the six metabolic genes we screened may be ideal prognostic markers.…”

Construction and validation of an RNA-binding protein-associated prognostic model for colorectal cancer

“…The TCGA cohort was used as the training group. ROC curve analysis showed that the nine gene markers had a better diagnostic ability and could select CRC patients with poor prognosis and AUC values of ROC, which was consistent with previous reports ( Jeun et al, 2019 ). Moreover, the validation group results (GEO cohorts) were consistent with the results from the training group.…”

Identification prognosis-associated immune genes in colon adenocarcinoma

“…In this study, our prognosis model is considered to be valuable. The 1-, 3-, and 5-year AUC value of ROC was 0.792, 0.744, and 0.797, respectively, which was more accurate than previous reports (30,31). The immune genes may be ideal prognostic markers.…”